While the reduction in price target could suggest a slightly less optimistic outlook on the stock's valuation, maintaining an Outperform rating indicates that Oppenheimer still sees positive potential in Lumos Pharma. The impact on the stock price is likely to be neutral in the short term as the positive rating balances the negative sentiment from the lowered target.